Unión Europea - español - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - antígenos de superficie del virus de la gripe (hemaglutinina y neuraminidasa) de la cepa a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vacunas - inmunización activa contra el subtipo h5n1 del virus influenza a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Unión Europea - español - EMA (European Medicines Agency)

novartis europharm limited - vildagliptina, metformin hidrocloruro - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 y 5. 1 para datos disponibles sobre diferentes combinaciones).

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

novartis farma produtos farmaceuticos sa - milbemicina oxima, prazicuantel - comprimido masticable - - combinaciones con milbemicina oxima - perros

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

novartis farma produtos farmaceuticos sa - milbemicina oxima, prazicuantel - comprimido masticable - - combinaciones con milbemicina oxima - perros

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

novartis farma produtos farmaceuticos sa - milbemicina oxima, prazicuantel - comprimido recubierto con pelÍcula - - combinaciones con milbemicina oxima - gatos

Unión Europea - español - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - inmunosupresores - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriásica arthritiscosentyx, solo o en combinación con metotrexato (mtx), está indicado para el tratamiento de la artritis psoriásica activa en pacientes adultos cuando la respuesta a la anterior modificadores de la enfermedad anti reumáticas de drogas (dmard), la terapia ha sido insuficiente. axial spondyloarthritis (axspa)espondilitis anquilosante (como, radiografía axial spondyloarthritis)cosentyx está indicado para el tratamiento de la espondilitis anquilosante activa en los adultos que han respondido de forma inadecuada a la terapia convencional. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Venezuela - español - Instituto Nacional de Higiene

novartis de venezuela s.a. - secukinumab -

Venezuela - español - Instituto Nacional de Higiene

novartis de venezuela, s.a. - secukinumab -

Venezuela - español - Instituto Nacional de Higiene

novartis de venezuela, s.a. - pasireotida - polvo para suspension inyectable - 20 mg

Venezuela - español - Instituto Nacional de Higiene

novartis de venezuela, s.a. - pasireotida - polvo para suspension inyectable - 40 mg